Aviva’s TG Therapeutics TGTX Stock Holding History

Aviva’s Portfolio TGTX Stock Details TGTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-27,259	Closed	-$638K	–	898
2024 Q3	$638K	Buy	+27,259	New	+$595K	﹤0.01%	768

Other funds holding TGTX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Pictet Asset Management Carouge, Switzerland $94.8B AUM 24.11% 1-Year Est. Return

SCM

Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return

Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Aviva's TGTX Position: Q4 2024 in Review

Aviva sold out of TG Therapeutics (TGTX) in Q4 2024, closing a stake of 27,259 shares — an estimated $638K sold.

Aviva first reported a position in TGTX in Q3 2024 and held it in 1 quarter. The position peaked at $638K in Q3 2024. 331 funds tracked by Wall St. Rank hold TGTX as of Q4 2024.

Aviva reported no remaining TG Therapeutics position as of Q4 2024 after selling out during the quarter.
Aviva sold 27,259 TG Therapeutics shares in Q4 2024, an estimated $638K.
Aviva first reported a position in TG Therapeutics in Q3 2024 and held it in 1 quarter.
Aviva's TG Therapeutics position peaked at $638K in Q3 2024.
331 funds tracked by Wall St. Rank held TG Therapeutics as of Q4 2024.

Based on Aviva's 13F filing for Q4 2024, filed 13 Feb 2025.